DYSF and limb-girdle muscular dystrophy: Therefore, immunohistochemistry and a genetic panel for LGMD using next-generation sequencing technology are particularly useful, as they can increase the sensitivity of LGMD2B diagnosis and play a key role in early treatment [17].